Chemours Co
Financial highlights
| Metric | FY 12/31/25 | FY 09/30/25 | FY 06/30/25 | FY 03/31/25 | FY 12/31/24 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.8B | — | — | — | $5.8B |
| Cost of revenue | $4.9B | — | — | — | $4.6B |
| Gross profit | $902.0M | — | — | — | $1.1B |
| Selling, general & administrative | $799.0M | — | — | — | $598.0M |
| Research and development | $108.0M | — | — | — | $109.0M |
| Operating expenses | $966.0M | — | — | — | $823.0M |
| Interest expense | $269.0M | — | — | — | $263.0M |
| Pretax income | -$277.0M | — | — | — | $106.0M |
| Income tax expense | $109.0M | — | — | — | $37.0M |
| Net income | -$386.0M | — | — | — | $69.0M |
| Balance Sheet | |||||
| Cash and equivalents | $670.0M | — | — | — | $713.0M |
| Current assets | $3.0B | — | — | — | $3.0B |
| Total assets | $7.4B | $7.5B | $7.5B | $7.4B | $7.5B |
| Current liabilities | $1.7B | $1.9B | $1.8B | $1.7B | $1.8B |
| Total liabilities | $7.1B | — | $7.2B | $6.8B | $6.9B |
| Stockholders' equity | $250.0M | $274.0M | $228.0M | $566.0M | $571.0M |
| Cash Flow Statement | |||||
| Cash from operations | $264.0M | — | — | — | -$633.0M |
| Depreciation and amortization | $340.0M | — | — | — | $292.0M |
| Stock-based compensation | $21.0M | — | — | — | $15.0M |
| Capital expenditure | $213.0M | — | — | — | $360.0M |
| Free cash flow | $51.0M | — | — | — | -$993.0M |
| Dividends paid | $78.0M | — | — | — | $148.0M |
| Impairments | $24.0M | — | — | — | $27.0M |
Shares outstanding 150.4M · Free float 98.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.